SEC Filing Summary: BioSig Technologies, Inc.
Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. on September 19, 2018. The registrant is incorporated in Delaware and maintains its principal executive offices in Los Angeles, California. The report addresses a specific corporate event regarding the listing of the company's securities.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance event rather than financial performance data.
Material Changes
The primary material event reported is the approval of BioSig Technologies, Inc.'s common stock for trading on the Nasdaq Capital Market. Trading on this exchange commenced on September 21, 2018.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors beyond the standard disclosures associated with a Form 8-K. The document incorporates a press release (Exhibit 99.1) by reference regarding the Nasdaq listing approval.
Investor Verification Checklist
- Verify the commencement date of trading on the Nasdaq Capital Market (September 21, 2018).
- Review the full text of the press release filed as Exhibit 99.1 for additional context on the listing approval.
- Confirm the company's current ticker symbol and trading status on the Nasdaq Capital Market.
- Note that this filing does not contain updated financial statements; refer to the most recent 10-K or 10-Q for financial data.